Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.
Skeletal unloading resulting from space flight and prolonged immobilization causes bone loss. Such bone loss ostensibly results from a rapid increase in bone resorption and subsequent sustained reduction in bone formation, but this mechanism remains unclear. Osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) is a recently identified potent inhibitor of osteoclast formation. We studied effects of OPG administration on tail-suspended growing rats to explore the therapeutic potential of OPG in the treatment and prevention of bone loss during mechanical unloading, such as that which occurs during space flight. Treatment with OPG in tail suspension increased the total bone mineral content (BMC g) of the tibia and femur and the total bone mineral density (BMD g/cm2) of the tibia. Moreover, treatment with OPG prevented reduction not only of BMC and BMD, but also of bone strength occurring through femoral diaphysis. Treatment with OPG in tail-suspended rats improved BMC, BMD and bone strength to levels of normally loaded rats treated with vehicle. Treatment with OPG in normally loaded rats significantly decreased urinary excretion of deoxypyridinoline, but the effect of OPG in tail suspension was unclear. These results indicate that OPG may be useful in inhibiting bone loss-engendered mechanical unloading.
Ichinose
Y
Y
Department of Pediatrics, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
Tanaka
H
H
Inoue
M
M
Mochizuki
S
S
Tsuda
E
E
Seino
Y
Y
D000596:Amino Acids / Q000652:urine; D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002118:Calcium / Q000097:blood; D004548:Elasticity / Q000187:drug effects; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D006023:Glycoproteins / Q000627:therapeutic use*; D019417:Hindlimb Suspension / Q000009:adverse effects; D008297:Male; D010010:Osteoclasts / Q000187:drug effects; D053244:Osteoprotegerin; D010758:Phosphorus / Q000097:blood; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013314:Stress, Mechanical; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D016474:Weight-Bearing / Q000502:physiology*
D000596:Amino Acids; D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506032:Tnfrsf11b protein, rat; D010758:Phosphorus; C036020:deoxypyridinoline; D002118:Calcium